Background
==========

Most psychiatric and neurodevelopmental disorders (PNDD) have a strong heritable component.[@R1] Twin studies have proved that neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD),[@R2] autism spectrum disorders (ASD),[@R2] as well as psychiatric conditions like Schizophrenia[@R3] (SCZ) and Bipolar Disorder[@R4] (BD) have an important genetic background. Nevertheless, until very recently, causal genes have only been found in the context of Intellectual Disability (ID). Classical genetic studies have failed to identify genes with high penetrance in PNDD, thus indicating that the genetic background of these disorders is highly heterogeneous.

Recent developments in DNA analysis and sequencing, such as next-generation sequencing, SNP arrays, exome sequencing or analysis of copy number variations (CNVs),[@R5]^,^[@R6] allow to study the whole genome of large cohorts of affected individuals, enabling the analysis of CNS disorders with highly heterogeneous genetic etiology. Several of these studies have focused on PNDDs, uncovering new genes with potential roles in these disorders. Interestingly, many of the genes identified are involved in synaptic physiology,[@R7] pointing towards synaptic dysfunction as an important contributing factor in many of these disorders.

Although numerous psychiatric conditions have traditionally been ascribed to unbalances in monoaminergic systems, it is also accepted that alterations in the glutamatergic system are involved in these disorders. In particular, an important group of genes expressed at the synapse identified in the context of PNDDs code for glutamate receptor subunits. Glutamate receptors (GluRs) mediate excitatory synaptic transmission and plasticity in the brain.[@R8] GluRs comprise three families of ionotropic receptors: AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), NMDA (*N*-methyl-D-Aspartate) and Kainate; as well as three groups of metabotropic receptors (mGluRs I-III). Ionotropic receptors are found as tetramers of various subunits: 4 *GRIA* genes code for AMPA subunits, 7 *GRIN* genes code for NMDA subunits and 5 *GRIK* genes code for Kainate subunits.[@R8] Finally, metabotropic receptors, which are G-protein coupled receptors, are coded by 8 *GRM* genes.[@R9] Functionally, ionotropic GluRs are specialized on different aspects of synaptic transmission. While NMDA receptors act as coincident detectors of postsynaptic membrane depolarization and glutamate release, AMPA receptors mediate fast transmission in excitatory synapses. Kainate receptors also participate in synaptic transmission and plasticity. On the other hand, metabotropic receptors modulate excitatory signaling.[@R8]^,^[@R9]

In this review we discuss recently identified mutations in GluR subunits in the context of PNDDs, including large genomic rearrangements directly affecting these genes or point mutations predicted to be deleterious. Linkage and association studies of natural variation, such as SNPs or microsatellites, have not been included in this work as these have a less direct implication in disease.

Mutations in AMPA Receptor Subunits
===================================

Of all four genes coding for AMPA receptor subunits,[@R8] only mutations in *GRIA2* and *GRIA3* have been related with PNDDs (Table 1). Alterations in these two genes have been associated with some cases of ASD,[@R10]^,^[@R11] but have mainly been found concomitant with ID.

Although chromosomal deletions encompassing *GRIA2* had been described for individuals with mental and developmental retardation (*see ref.* [@R12] *for review*), only recent studies have identified specific mutations in *GRIA2* in the context of ID,[@R12]^,^[@R13] suggesting that *GRIA2* haploinsufficiency might cause ID.

*GRIA3* was first identified as a candidate gene for X-linked ID in 1999, in a female with a balanced translocation directly involving this gene.[@R14] Since then, several other *GRIA3* mutations have been associated with ID, including complete[@R15]^,^[@R16] or partial duplications,[@R17]^,^[@R18] mutations on its 5′UTR[@R19] and a whole gene deletion.[@R20] Interestingly, both duplications and deletions of *GRIA3*, translate into a diminished or absent synthesis of GluA3 protein. Partial duplications would cause either reduced *GRIA3* transcripts or aberrant protein levels ultimately contributing to ID. Missense *GRIA3* variants[@R20] have also been found linked to ID and, with the exception of the G833R mutation (see Table 1) these individuals express *GRIA3* at normal levels. Nevertheless, when functionally tested GluA3 variants displayed altered channel function either in homomeric combination or in heteromers with normal GluA2.[@R20]

GluA3 is normally present at synapses together with GluA2 contributing to the normal cycling of AMPA receptors.[@R8] From the studied individuals with ID, it can be inferred that the lack of GluA3 is not crucial for neuronal viability. In fact, synaptic targeting and function of these receptors are not significantly altered in GluA3 KO mice.[@R21] Remarkably, long-term potentiation (LTP), widely thought to be the cellular basis of learning processes,[@R22] is abnormal in these animals. Nevertheless, in humans, the lack of GluA3 could impair normal neuronal wiring or stabilization of activated synapses during development.

AMPA receptor auxiliary subunits, TARPs and CNIHs,[@R23] control receptor function by modulating channel trafficking and kinetics. It is interesting to note that a mutation affecting *CACNG2* (TARP γ-2) has been described in an individual with moderate ID.[@R24] This mutation caused a decreased association with AMPA subunits, altering the receptor trafficking and reducing mEPSCs in hippocampal neurons. Finally, *CNIH2* deletion has also been found in a boy with mild ID.[@R25] Thus, it is noteworthy that malfunctions of AMPA receptor auxiliary can also be associated with ID.

Mutations in NMDA Receptor Subunits
===================================

NMDA subtype of ionotropic GluRs play a pivotal role in neuronal communication. These receptors are composed of two obligatory subunits (GluN1) and two variable ones, which consist of either GluN2(A-D) or GluN3(A,B).[@R26] Of the variable subunits, GluN2B expression starts very early in development and is critical for synaptogenesis and neuronal survival in cortical brain areas, thus making it a candidate factor in neurodevelopmental disorders. Indeed, *GRIN2B* is the most frequently mutated *GRIN* gene (see Table) in PNDDs, being mainly related with ID.[@R27]^-^[@R30] Specific *GRIN2B* gain-of-function mutations have also been associated with ASD, supporting the hypothesis of an imbalance between excitatory and inhibitory neurotransmission in ASD etiology,[@R31]^,^[@R32] as well as in West Syndrome with severe developmental delay.[@R27] *GRIN2A* gene codes for GluN2A subunit, which is broadly expressed in adult brain. *GRIN2A* de novo mutations[@R30] and microdeletions[@R33] have also been associated to ID, indicating the viability of GluN2A haploinsufficiency. A different group of *GRIN2A* mutations have also been associated with ASD.[@R34]^,^[@R35] Likewise, a rare *GRIN2A* de novo mutation was recently associated with schizophrenia,[@R31] although the role of GluN subunits with SCZ is under debate.[@R36] Although less frequently, mutations in *GRIN1* gene, the obligatory NMDA receptor subunit, have also been identified. A mutation in *GRIN1* has been found to cause non-syndromic intellectual disability (NSID), an observation functionally validated using cellular models.[@R24]

Interestingly, regarding *GRIN2C*, *GRIN3A* and *GRIN3B*, only rare truncating mutations affecting both healthy individuals and ASD/SZ patients[@R31] have been reported. In contrast, no truncating mutations were found in *GRIN1*, *GRIN2A*, *GRIN2B* and *GRIN2D* genes, suggesting a more critical function of these genes during neurodevelopment and the lethality of the putative loss-of-function. Taken together, these recent reports suggest that de novo mutations of NMDAR subunits are frequently associated with ID, although some specific mutations are also associated with psychiatric diseases.

Mutations in Kainate Receptor Subunits
======================================

Previous classic genetic association studies suggested linkages to mood disorders for some of the kainate receptor-encoding genes, mainly *GRIK2* and *GRIK3* (*see ref.* [@R37] *for review*). More recently, CNVs in *GRIK2* were found enriched in, but not exclusive of, children with ID, indicating limited pathogenic burden.[@R38] Interestingly, a complex loss-of-function mutation in *GRIK2* was found to co-segregate with NSID.[@R39] This *GRIK2* mutation involves various deletions and inversions spanning exons 7 to 11, resulting in loss of the first ligand-binding domain, the adjacent transmembrane domain, and the putative pore loop of GluK2. Moreover, GluK2 mutants showed complete absence of currents despite normal cell surface expression. This study strongly indicates that loss of GluK2 protein can cause severe-to-moderate cognitive impairment in humans.

A *GRIK4* variant with an insertion-deletion in the 3′UTR region (which results in increased GluK4 levels) was found to confer protection against bipolar disorder.[@R40] Moreover, this *GRIK4* variant increased hippocampal activation during face processing,[@R41] suggesting a link between kainate receptor-mediated excitation in the hippocampus and Bipolar Disorder.

So far, the subfamily of kainate glutamate receptors is the one for which less mutations have been identified in the context of PNDDs. However, collectively taken, these results support the notion that mutations leading to up- or down-regulation of kainate subunits can cause learning disabilities and modulate mood disorders.

Mutations in Metabotropic Receptor Subunits
===========================================

Currently, a limited number of papers report deleterious mutations related to PNDDs in *GRMs* (see [**Table 1**](#T1){ref-type="table"}). Of these, two performed *GRM1* exon sequencing in SCZ and BD,[@R42]^,^[@R43] another sequences the *GRM3* gene in a cohort of individuals with BD[@R44] and one performed a genome-wide copy number variation (CNV) association study[@R45] on attention deficit hyperactivity disorder (ADHD). Finally, a mutation in the Kozak's sequence of *GRM3*assocaited with SCZ has also been reported .[@R46]

###### Contribution of glutamate receptor subunit mutations to psychiatric and neurodevelopmental disorders

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mutated gene             Neurological disorder                               Mutation                                                    Altered function(s)                                                      Reference
  ------------------------ --------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------ -----------
  GRIA2                    ASD                                                 Deletion                                                    Haploinsufficiency                                                       10

  ID                       Complete deletion                                   Haploinsufficiency                                          12                                                                       

  ID                       Truncation                                          Haploinsufficiency                                          13                                                                       

  GRIA3                    ID                                                  Interruption by breakpoint translocation t(X;12)(q24;q25)   nd                                                                       14

  ASD and ID               Complete duplication                                nd                                                          15                                                                       

  ID                       Complete duplication                                nd                                                          16                                                                       

  ASD                      Partial tandem duplication (4 exons)                nd                                                          11                                                                       

  ID                       Partial tandem duplication (5 exons)                Reduced transcripts                                         17                                                                       

  ID                       Partial tandem duplication (12 exons)               Aberrant transcripts with premature termination codon       18                                                                       

  ID                       Duplication 874-bp upstream GRIA3                   Absence of transcripts                                      19                                                                       

  ID                       Complete deletion                                   nd                                                          20                                                                       

  ID                       R450Q                                               Accelerated receptor desensitization kinetics               20                                                                       

  ID                       R631                                                Decreased channel function                                  20                                                                       

  ID                       M706T                                               Decreased channel function                                  20                                                                       

  ID                       G833R                                               Protein miss-folding and degradation                        20                                                                       

  CACNG2                   ID                                                  V143L                                                       Altered binding to AMPARs, reduced AMPARs expression, decreased mEPSCs   24

  CNIH2                    ID                                                  Complete deletion                                           nd                                                                       25

  GRIK2                    NSID                                                Deletion and inversion                                      Abolished channel function                                               39

  GRIK4                    BD                                                  Insertion-deletion                                          Overexpression                                                           40

  GRIN1                    NSID                                                E662K                                                       nd                                                                       24

  NSID and Epilepsy        S560dup                                             Decreased channel function                                  24                                                                       

                           SZ                                                  A968T, 3669C- \> T (silent)                                 nd                                                                       31

                           ID                                                  Microdeletions                                              nd                                                                       33

  GRIN2A                   ID                                                  L649V, P522R                                                nd                                                                       30

                           ASD                                                 Copy number variation                                       nd                                                                       35

  GRIN2B                   West syndrome with dvpt delay                       N615I, V618G                                                Reduced Mg^2+^ blockade and increased Ca^2+^ permeability                27

  ID with focal epilepsy   R540H                                               Mild changes of channel function                            27                                                                       

  ASD                      L825V                                               nd                                                          31                                                                       

  ID                       c.411+1G \> A, 2360--2A \> G, T268SfsX, R682A\      nd                                                          28                                                                       
                           Translocation breakpoints disrupting *GRIN2B*                                                                                                                                            

  ID                       P553L                                               nd                                                          30                                                                       

  ASD with ID              Single-base substitution at Exon10 3′ splice site   nd                                                          34                                                                       

  ASD                      S34GInfsX25, C456Y, W559X, 2172--2A \> G            nd                                                          34                                                                       

  ID                       Micorodeletions of *GRIN2B* locus                   nd                                                          29                                                                       

  GRIN2C                   ASD                                                 W18X (truncation)                                           nd                                                                       31

  GRIN3A                   SZ                                                  Q508X, E227X                                                nd                                                                       31

  GRM1                     SZ                                                  F122L, A683E, P970L, P1015A                                 Low Inositol Phosph.                                                     43

  SZ                       P1014S                                              Low Membrane Expr.                                          43                                                                       

  ADHD                     Duplication (8 cases 2 controls)                    nd                                                          45\*                                                                     

  SZ                       L575V, L602M, I604M                                 nd                                                          47                                                                       

  BP                       T548M                                               nd                                                          47                                                                       

  GRM3                     BP                                                  Kozak sequence variant (19 cases, 4 controls)               Altered expression (predicted)                                           44

  SZ                       Haplotype in intron 2                               Lower glutamate levels (MRI)                                46                                                                       

  GRM5                     ADHD                                                Deletion (10 cases 1 control)                               nd                                                                       45\*

  GRM7                     ADHD                                                Deletion (6 cases)                                          nd                                                                       45\*

  GRM8                     ADHD                                                Deletion (8 cases)                                          nd                                                                       45\*
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ID, intellectual disability; NSID, non-syndromic ID; ASD: autism spectrum disorder; BD, bipolar disorder; SCZ, schizophrenia; ADHD, attention deficit hyperactivity disorder; \*copy number variation study with average CNV size of 62Kb

It is important to highlight that, as it happens with genes giving susceptibility to psychiatric diseases,[@R1] none of the reported mutations supports for a causal role in disease. In most cases, *GRMs* mutations are observed in both cases and controls. Quite surprisingly, this is even the case for whole gene deletions or duplications.[@R45] The small number of mutations identified for *GRMs* make it still difficult to conjecture on their relevance to disease.

Nevertheless, a striking observation can be made: there is no report implicating *GRM* mutations in neurodevelopmental disorders such as ID or ASD. Despite the extensive literature on the role of these receptors, especially *GRM1* and *GRM5*, in Fragile X-Syndrome and ASD,[@R47]^,^[@R48] deleterious mutations on *GRMs* have so far been found only in the context of psychiatric disorders, such as SCZ, BP or ADHD.

Closing Remarks
===============

Recently developed DNA analysis tools are allowing for the rapid uncovering of GluRs mutations in the context of PNDDs. This can be seen by the exponential increase in the number of papers reporting GluR mutations in most recent years. Based on this, we expect that new GluR mutations will be identified in the future, hopefully allowing for a better understanding of GluR etiological contribution to PNDDs. Although the number of studies reporting GluR mutations in PNDD is so far restricted, some initial conclusions can be drawn. These will need to be examined in the light of future studies.

In the first place, mutations of subunits of some receptor subtypes are related to certain disease types but not to others. In this regard, mutations in AMPA subunits have only been found in the context of ID and ASD, both neurodevelopmental disorders. Similarly, mutations in genes coding for AMPAR auxiliary proteins are also related with ID. Along these lines, mutations in NMDA subunits are mostly linked to ID and ASD. In stark contrast, mutations in metabotropic receptors are only related to psychiatric disorders. Accordingly, the data available would suggest that mutations in ionotropic glutamate receptors predispose towards neurodevelopmental disorders, while mutations in metabotropic receptors would predispose towards psychiatric disorders. One can also draw a parallel between the extent of mental disability and the contribution to neurotransmission of the affected receptor type. Thus, loss-of-function mutations in AMPA and NMDA subunits are frequently found in patients with ID. This is consistent with their important role in neuronal development, fast transmission, and synaptic plasticity. On the other hand, the abundance of *GRM* mutations in individuals with psychiatric disorders is consistent with the more modulatory role of mGluRs. The occurrence of ID in carriers of a mutant GluK2 suggests that tuning of neuronal network activity by kainate receptors can have profound effects on cognitive abilities.

Secondly, mutation rates amongst GluR are very heterogeneous in PNDDs. Indeed, while some genes accumulate many potentially deleterious mutations, no mutations have been found in others. Amongst AMPA subunits, for instance, *GRIA1* and *GRIA4* have not been found mutated in the context of PNDD, while twelve different mutations have been described for *GRIA3.* Similarly, few mutations are found in *GRIN1* as compared to *GRIN2A* or *GRIN2B*. Remarkably, the spectrum of mutations in NMDA subunits concentrates in particular coding regions, namely, the extracellular and pore-forming domains. This observation suggests that impaired ion selectivity and conductance of NMDA receptors is closely linked to developmental defects, while the role of its intracellular tail might have a less critical role in disease. There are several potential explanations why some GluR genes do not appear mutated in relation to disease; they might play indispensable biological functions, thus leading to lethality even in heterozygosity, or other molecules could compensate for their dysfunction.

Interestingly, we do not see an increased number of mutations in GluR subunits expressed early in development, which a priori, should be more relevant to neurodevelopmental disorders. For instance, a similar number of mutations has been found for *GRIN2B*, which starts to be expressed early in development, and for *GRIN2A*, that is expressed post-natally.[@R49] In contrast, no mutations have been described for *GRIA4*, also highly expressed during development.[@R50] Nevertheless, this observation should be taken cautiously as mutations in developmental genes could cause lethality and also because gene expression data, mostly obtained from rodent species, might not be completely valid for humans.

Although the etiopathology of PNDDs is complex and multigenic, a growing set of genetic and functional evidences indicate the contribution of glutamate receptors in these damaging disorders. The following years will be crucial to understand whether the different receptor subunits are associated with certain PNDDs or not, as well as their interaction with genetic background and environmental factors.
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:   psychiatric and neurodevelopmental disorders

ADHD

:   attention deficit hyperactivity disorder
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:   autism spectrum disorders
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:   Bipolar Disorder

SCZ

:   Schizophrenia

ID

:   Intellectual Disability

AMPA

:   α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

NMDA

:   *N*-methyl-D-Aspartate

mGluR

:   metabotropic G-protein coupled glutamate receptor
